Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
92 hedge funds and large institutions have $782M invested in Apellis Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 17 closing their positions.
85% more capital invested
Capital invested by funds: $423M → $782M (+$359M)
25% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 28
14.2% more ownership
Funds ownership: 57.09% → 71.28% (+14%)
0% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $1.46M
3% less funds holding
Funds holding: 95 → 92 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$60.7M |
| 2 |
O
OrbiMed
New York
|
+$22.6M |
| 3 |
Morgan Stanley
New York
|
+$18.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$14.1M |
| 5 |
Millennium Management
New York
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$14.2M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.72M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.92M |
| 4 |
NTC
NF Trinity Capital
Central,
Hong Kong
|
-$4.71M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
-$4.15M |
APLS Hedge Fund Activity: Q1 2019 in Review
92 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2019, worth a combined $782M — up 85% from $423M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of APLS and 14 opened new positions — a net loss of 3 holders — while 28 trimmed existing stakes and 35 added.
The largest buyer was Wellington Management Group, adding an estimated $60.7M. The largest seller was Cormorant Asset Management, cutting an estimated $14.2M.
- 92 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2019, down from 95 in Q4 2018.
- Funds reported $782M of Apellis Pharmaceuticals stock for Q1 2019, up 85% quarter-over-quarter.
- 14 funds opened new Apellis Pharmaceuticals positions in Q1 2019 and 17 closed out, a net change of -3 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2019 was Wellington Management Group, an estimated $60.7M added.
- The largest Apellis Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2019.